Related Posts

Nivolumab found to extend lives of relapsed patients who had run out of therapy options An immunotherapy drug hailed as a potential “gamechanger” in the treatment of cancer could soon offer new hope to patients with currently untrea...

In a head-to-head clinical trial comparing standard chemotherapy with the immunotherapy drug nivolumab, researchers found that people with squamous-non-small cell lung cancer who received nivolumab lived, on average, 3.2 months long...

(Institute of Cancer Research) An immunotherapy drug has been hailed as a potential 'game changer' after being found to greatly improve survival for patients with relapsed head and neck cancer -- a disease which is notoriously diffi...

The immunotherapy drug nivolumab has become the first to show a survival benefit in head and neck cancer, after a major international trial found that it was more effective than standard chemotherapy.
Patients taking nivolumab were ...